Vertex signs $220M deal with Genomics to re-up long-running discovery pact

Robot hands with a pieces of the puzzle
Vertex first tapped Genomics in 2018 to make use of the company's discovery platform that incorporates a genetic database and analytic tools to reveal new disease targets. (iStock/Getty Images Plus)

Vertex Pharmaceuticals has re-upped its ties with sequencing specialist Genomics in a deal worth up to $220 million, signing on for another four years on top of the eight the companies have already worked together.

The two initially joined forces in 2018 to make use of Genomics’ discovery platform, which incorporates a genetic database and analytic tools to reveal new disease targets. Vertex poured $13.7 million into the investment at the time.

The new deal value is subject to research, development, regulatory and commercial milestones, and includes potential royalties, according to a Nov. 18 release. Vertex did not give a detailed breakdown of the agreement's financial structure.

And while the exact programs to which Genomics has contributed have not been disclosed, Vertex said in its announcement that the companies “will continue to work closely together to incorporate their deep understanding of human genetics into research and development.”

Genomics has built what it describes as the largest and most diverse human genotype-phenotype database with its Mystra platform, bringing together over 45,000 genome-wide association studies. The company also launched an AI version of its platform in June.

“A deep understanding of human genetics and the underlying causal biology of diseases is foundational to how we discover and develop transformational therapies,” Vertex chief scientific officer Mark Bunnage said in a statement. “Over nearly a decade together, Genomics has proven to be an exceptional partner, combining sophisticated data science with deep genetic insights, and I’m delighted to be extending our productive partnership.”